Lyell Immunopharma Completes ImmPACT Bio Acquisition
Deal News | Oct 31, 2024 | Globenewswire
Lyell Immunopharma, a clinical-stage company pioneering next-generation CAR T-cell therapies, has announced the completion of its acquisition of ImmPACT Bio USA Inc., a privately-held cell therapy firm. This acquisition enhances Lyell’s pipeline with the dual-targeting CD19/CD20 CAR T-cell product candidate, IMPT-314. The new candidate is set to undergo pivotal development in 2025, targeting patients with B-cell non-Hodgkin lymphoma who have not been exposed to CAR T-cell therapy. The acquisition also brings Sumant Ramachandra, the former CEO of ImmPACT, to Lyell’s Board of Directors. This strategic move aims to accelerate Lyell's development of durable therapies for hematologic malignancies. The company anticipates the financial capability to sustain operations through critical clinical milestones until 2027.
Sectors
- Biotechnology
- Pharmaceuticals
Geography
- United States – Lyell Immunopharma and ImmPACT Bio are located within the United States, with operations affecting the American biotechnology and pharmaceutical landscape.
Industry
- Biotechnology – The acquisition involves companies dedicated to biotechnology and cell therapy solutions, focusing on advanced medical treatments for hematologic malignancies.
- Pharmaceuticals – Both firms work within the pharmaceuticals sector, developing innovative biologic therapies for cancer treatment.
Financials
- 2027 – Projected financial runway for Lyell Immunopharma to maintain operations through 2027, covering critical clinical milestones.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Lyell Immunopharma, Inc. | Acquirer | Company | A clinical-stage company focused on developing CAR T-cell therapies. |
| ImmPACT Bio USA Inc. | Target | Company | A privately-held clinical-stage cell therapy company. |
| Sumant Ramachandra, M.D., Ph.D., MBA | New Board Member | Person | Former Chief Executive Officer of ImmPACT Bio and newly appointed member of Lyell’s Board of Directors. |
| Lynn Seely, M.D. | President and CEO | Person | President and Chief Executive Officer of Lyell Immunopharma. |
| Rick Klausner, M.D. | Board Chair | Person | Chair of the Board of Directors at Lyell Immunopharma. |